Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Leptomeningeal Disease
NCT03091478Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2017
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in leptomeningeal carcinomatosis (LMC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Number of Participants With a Response at 12 weeks. Started Apr 2017; status: terminated.
02
Drugs
03
Conditions
leptomeningeal carcinomatosis (LMC)
Beyond the preview
Go deeper on NCT03091478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03091478.